Literature DB >> 30957058

Systemic Immunotherapy Effective for Refractory Extramedullary Acute Myeloid Leukemia.

Mansour Alfayez1, Doina Ivan2, Naveen Pemmaraju1, Naval Daver1, Courtney D DiNardo1.   

Abstract

Entities:  

Keywords:  Acute myeloid leukemia; Immune checkpoint inhibitors; Ipilimumab; Nivolumab; PD-1; extramedullary AML; hypomethylating agent

Year:  2019        PMID： 30957058      PMCID： PMC6448807          DOI： 10.1200/PO.18.00198

Source DB:  PubMed          Journal:  JCO Precis Oncol        ISSN： 2473-4284


× No keyword cloud information.
  20 in total

1.  Mutated regions of nucleophosmin 1 elicit both CD4(+) and CD8(+) T-cell responses in patients with acute myeloid leukemia.

Authors:  Jochen Greiner; Yoko Ono; Susanne Hofmann; Anita Schmitt; Elmar Mehring; Marlies Götz; Philippe Guillaume; Konstanze Döhner; Joannis Mytilineos; Hartmut Döhner; Michael Schmitt
Journal:  Blood       Date:  2012-05-16       Impact factor: 22.113

2.  Immune responses against the mutated region of cytoplasmatic NPM1 might contribute to the favorable clinical outcome of AML patients with NPM1 mutations (NPM1mut).

Authors:  Jochen Greiner; Vanessa Schneider; Michael Schmitt; Marlies Götz; Konstanze Döhner; Markus Wiesneth; Hartmut Döhner; Susanne Hofmann
Journal:  Blood       Date:  2013-08-08       Impact factor: 22.113

3.  Combined Cytosine-arabinoside plus interferon-alpha .2. Clinical-studies in leukemia and lymphoma.

Authors:  W Bezwoda; L Seymour; P Ruff
Journal:  Int J Oncol       Date:  1993-03       Impact factor: 5.650

4.  Attempts to improve treatment outcomes in acute myeloid leukemia (AML) in older patients: the results of the United Kingdom Medical Research Council AML11 trial.

Authors:  A H Goldstone; A K Burnett; K Wheatley; A G Smith; R M Hutchinson; R E Clark
Journal:  Blood       Date:  2001-09-01       Impact factor: 22.113

5.  Expression of co-stimulatory molecules on acute myeloid leukaemia blasts may effect duration of first remission.

Authors:  Alastair Whiteway; Tim Corbett; Robert Anderson; Ian Macdonald; H Grant Prentice
Journal:  Br J Haematol       Date:  2003-02       Impact factor: 6.998

6.  Programmed death ligand 1 is expressed by non-hodgkin lymphomas and inhibits the activity of tumor-associated T cells.

Authors:  David J Andorsky; Reiko E Yamada; Jonathan Said; Geraldine S Pinkus; David J Betting; John M Timmerman
Journal:  Clin Cancer Res       Date:  2011-05-03       Impact factor: 12.531

7.  Graft-versus-leukemia reactions after bone marrow transplantation.

Authors:  M M Horowitz; R P Gale; P M Sondel; J M Goldman; J Kersey; H J Kolb; A A Rimm; O Ringdén; C Rozman; B Speck
Journal:  Blood       Date:  1990-02-01       Impact factor: 22.113

8.  Functional characterization of T lymphocytes derived from patients with acute myelogenous leukemia and chemotherapy-induced leukopenia.

Authors:  Øystein Wendelbo; Ingerid Nesthus; Malvin Sjo; Kristin Paulsen; Peter Ernst; Øystein Bruserud
Journal:  Cancer Immunol Immunother       Date:  2004-05-05       Impact factor: 6.968

9.  Donor lymphocyte infusion in the treatment of first hematological relapse after allogeneic stem-cell transplantation in adults with acute myeloid leukemia: a retrospective risk factors analysis and comparison with other strategies by the EBMT Acute Leukemia Working Party.

Authors:  Christoph Schmid; Myriam Labopin; Arnon Nagler; Martin Bornhäuser; Jürgen Finke; Athanasios Fassas; Liisa Volin; Günham Gürman; Johan Maertens; Pierre Bordigoni; Ernst Holler; Gerhard Ehninger; Emmanuelle Polge; Norbert-Claude Gorin; Hans-Jochem Kolb; Vanderson Rocha
Journal:  J Clin Oncol       Date:  2007-10-01       Impact factor: 44.544

10.  PD-1/PD-L1 interactions inhibit antitumor immune responses in a murine acute myeloid leukemia model.

Authors:  Long Zhang; Thomas F Gajewski; Justin Kline
Journal:  Blood       Date:  2009-05-05       Impact factor: 22.113
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.